Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2022 | Developments in biomarkers for MS susceptibility and prodrome

Raphael Schneider • 2 Mar 2022
ACTRIMS 2022
Multiple Sclerosis and Related Disorders

Raphael Schneider, MD, PhD, FRCPC, CIP, St. Michael’s Hospital, Toronto, Canada, outlines the potential use of neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) as biomarkers for susceptibility and onset of multiple sclerosis (MS). Dr Schneider explains that testing for an increase in NfL or GFAP, in the plasma or serum of a patient with radiologically isolated syndrome (RIS), is easier than using multiple biomarkers and complex technology to analyze the immune cell compartment. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.

More from Raphael Schneider

Multiplex proteomics reveals a distinct inflammatory signature in RIS
3:07
Multiplex proteomics reveals a distinct inflammatory signature in RIS
Raphael Schneider • 9 Feb 2026
Predicting symptom onset in RIS using combined biomarker approaches
1:55
Predicting symptom onset in RIS using combined biomarker approaches
Raphael Schneider • 9 Feb 2026
Assessing the peripheral immune compartment of patients with RIS
5:27
Assessing the peripheral immune compartment of patients with RIS
Raphael Schneider • 3 Mar 2022
Potential use of MRI sequencing in the clinical setting of MS
1:03
Potential use of MRI sequencing in the clinical setting of MS
Raphael Schneider • 2 Mar 2022

Related Videos

What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
6:48
What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
Mar Tintoré • 3 Jul 2026
The emerging role of AI in the diagnosis and management of multiple sclerosis
1:55
The emerging role of AI in the diagnosis and management of multiple sclerosis
Celia Oreja-Guevara • 29 Jun 2026
Ovarian aging and long-term prognosis in women with multiple sclerosis
3:07
Ovarian aging and long-term prognosis in women with multiple sclerosis
Mar Tintoré • 3 Jul 2026
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
3:15
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
Franz Felix Konen • 28 Jul 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals